|
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial
|
Written by: J. Smith |
Hits: 407
|
|
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
|
Written by: J. Smith |
Hits: 325
|
|
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
|
Written by: J. Smith |
Hits: 661
|
|
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
|
Written by: J. Smith |
Hits: 670
|
|
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
|
Written by: J. Smith |
Hits: 311
|
|
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
|
Written by: J. Smith |
Hits: 402
|
|
Liraglutide Reduces BMI in Children Under 12 With Obesity, But Questions Remain
|
Written by: J. Smith |
Hits: 309
|
|
Dexcom G7 15-Day CGM Wins FDA Clearance
|
Written by: J. Smith |
Hits: 599
|
|
Rybelsus® Cuts Cardiovascular Risk by 14% in SOUL Trial
|
Written by: J. Smith |
Hits: 494
|
|
Ozempic® Shows New Benefit for People with Type 2 Diabetes and PAD
|
Written by: J. Smith |
Hits: 840
|
